Patents by Inventor Lisa Michelle Ebert

Lisa Michelle Ebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND PRODUCTS FOR DETERMINING RESPONSIVENESS TO ANTI-PD1 IMMUNE CHECKPOINT INHIBITOR IMMUNOTHERAPY
    Publication number: 20260016474
    Abstract: The present invention provides methods, systems, and kits for determining responsiveness of a subject with or susceptible to cancer to anti-PD1 immune checkpoint inhibitor immunotherapy (ICII) including determining the level of one or more of markers CD15 in CD8+Ki67/CD71+ or CD8/CD4?Ki67/CD71+ T cells, CTLA-4 in CD4+Ki67/CD71+ T cells, FoxP3 in CD4+Ki67/CD71+ T cells, Ki67 or CD71 in CD8+ T cells, wherein an increase in CD15, CTLA-4, FoxP3, or a decrease in Ki67 or CD71 prior to immunotherapy is indicative that the subject is responsive to immunotherapy, particularly PD1 ICII.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 15, 2026
    Applicants: University of South Australia, Central Adelaide Local Health Network Inc
    Inventors: Lisa Michelle Ebert, Michael Paul Brown, Nga Thi Hong Truong
  • METHODS, PRODUCTS AND SYSTEMS FOR PROGNOSIS OF SUBJECTS SUFFERING FROM MULTIPLE MYELOMA
    Publication number: 20240110915
    Abstract: The present disclosure relates to methods, products and systems for the prognosis of subjects suffering from multiple myeloma. In certain embodiments, the present disclosure provides a method of prognosis for a subject suffering from multiple myeloma. The method comprises determining the level of desmoglein 2 (DSG2) in malignant plasma cells from the subject, wherein an increased level of DSG2 in the plasma cells is indicative of a poorer prognosis for the subject.
    Type: Application
    Filed: November 16, 2021
    Publication date: April 4, 2024
    Applicants: University of South Australia, Central Adelaide Local Health Inc, The University of Adelaide
    Inventors: Craig Thomas Wallington-Beddoe, Claudine Sharon Bonder, Lisa Michelle Ebert
  • Expression of FoxP3 by cancer cells
    Patent number: 8420791
    Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: April 16, 2013
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis
  • EXPRESSION OF FOXP3 BY CANCER CELLS
    Publication number: 20100143359
    Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 10, 2010
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis